The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 5, 2000, Pages 403-416

  Zaric, Gregory S ^a   Bayoumi, Ahmed M ^b   Brandeau, Margaret L ^c   Owens, Douglas K ^d,e,f  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Stanford University   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

Cost effectiveness; HIV; HIV screening

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; POSTNATAL CARE; PREGNANCY; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; SERODIAGNOSIS; UNITED STATES;

EID: 0034671912     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200012150-00004     Document Type: Article

References (105)

1. Committee on Pediatric AIDS Surveillance of pediatric HIV infection
2. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
3. Update: Perinatally acquired HIV/AIDS - United States, 1997
4. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States
5. A minimum estimate of the number of living HIV infected persons confidentially tested in the United States
6. Legal considerations in screening pregnant women for human immunodeficiency virus
7. Compliance with voluntary prenatal HIV testing in a large health maintenance organization (HMO)
8. Newborn human immunodeficiency testing in New York: A legislative quandary
9. Protecting the weakest link: A proposal for universal, unblinded pediatric HIV testing, counselling and treatment
10. The case against mandatory newborn screening for HIV antibodies
11. Bill would order AIDS-virus testing to protect babies
12. HIV screening of newborns
13. HIV mass screening of infants and mothers: Historical, technical, and practical issues
14. Routine testing of HIV status of babies
15. HIV testing for newborns debated anew
16. Treatment of HIV infection in infancy
17. Risk of human immuno-deficiency virus type 1 transmission through breastfeeding
18. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
19. Pediatric HIV disease, zidovudine in pregnancy, and unblinding heelstick surveys: Reframing the debate on prenatal HIV testing
20. Prevention of perinatal transmission of human immunodeficiency virus: A progress report two years after completion of AIDS clinical trials group trial 076
21. A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants
22. Treatment with indinavir, zidovudine, and lamivudine in adults with human immuno-deficiency virus infection and prior antiretroviral therapy
23. Identification of levels of maternal H1V-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load
24. Antiretroviral therapy for pregnant women
25. Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the pediatric spectrum of disease project
26. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols
27. Lifetime cost of care for children with human immunodeficiency virus infection
28. Pediatric human immunodeficiency virus infection: Recent evidence on the utilization and costs of health services
29. Screening surgeons for HIV infection: A cost-effectiveness analysis
30. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
31. Screening women of childbearing age for human immunodeficiency virus: A model-based policy analysis
32. Are medical students ready to provide HIV-prevention counseling?
33. Correlates of acceptance of HIV testing and post-test counseling in the obstetrical setting
34. Breastfeeding among HIV-infected women, Los Angeles and Massachusetts, 1988-1993
35. Routine prenatal screening for HIV infection
36. Trends in the percentage of women who received no prenatal care in the United States, 1980-1992: Contributions of the demographic and risk effects
37. A review of problems of universal access to prenatal care
38. Adequacy of prenatal care utilization - California, 1989-1994
39. Prenatal care in the United States, 1980-94
40. Drawing women into prenatal care
41. Expanded Medicaid coverage for pregnant women to 100 percent of the federal poverty level
42. The effect of providing health coverage to poor uninsured pregnant women in Massachusetts
43. Human immunodeficiency virus test refusal in pregnancy: A challenge to voluntary testing
44. Prenatal care of HIV-infected women: Analysis of a large New York state cohort
45. Determinants of acceptance of routine human immunodeficiency virus testing in an inner city prenatal population
46. Routine antepartum human immunodeficiency virus infection screening in an innercity population
47. Breast-feeding in a lowincome population
48. Perinatal determination of demographic and attitudinal factors regarding feeding practice in an indigent population
49. Does WIC participation improve breast-feeding practices?
50. The effect of postpartum lactation counseling on the duration of breast-feeding in low-income women
51. Breast-feeding rates among black urban low-income women: Effect of prenatal education
52. The cost-effectiveness of HIV testing: Accounting for differential participation rates
53. Success in implementing public health service guidelines to reduce perinatal transmission of HIV - Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996
54. The changing pattern of prenatal care utilization in the United States, 1981-1995, using different prenatal care indices
55. HIV testing patterns: Where, why, and when were persons with AIDS tested for HIV?
56. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center
57. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina
58. Breastfeeding and disease progression among perinatally HIV-infected children in Los Angeles County
59. Antenatal HIV testing: Assessment of a routine voluntary approach
60. Mandatory HIV testing of infants and rates of follow-up care
61. A four state evaluation of ZDV use to reduce perinatal HIV transmission
62. The value of patientreported adherence to antiretroviral therapy in predicting virologic and immunologic response
63. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women
64. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study
65. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
66. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
67. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
68. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand
69. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand
70. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis
71. The case for rapid HIV testing during labor
72. Viral load and heterosexual transmission of human immunodeficiency virus type 1
73. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant
74. Assessment of maternal plasma HIV viral load as a correlate of vertical transmission
75. Maternal virus load during pregnancy and mother-to-child transmission of human immuno-deficiency virus type 1: The French perinatal cohort studies
76. The effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women
77. The effect of maternal viral load on the risk of perinatal transmission of HIV-1
78. Natural history of vertically acquired human immunodeficiency virus-1 infection
79. Human immunodeficiency virus type I infection and breast milk
80. Interpretation of cost-effectiveness analyses
81. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. Technical guidance on HIV counseling
82. Cost-effectiveness of HIV screening in acute care settings
83. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: A cost-effectiveness analysis
84. The cost-effectiveness of human immunodeficiency virus screening in pregnancy
85. Preventing perinatal transmission of HIV - Costs and effectiveness of a recommended intervention
86. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine
87. Universal HIV screening of pregnant women in England: Cost effectiveness analysis
88. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: A cost-effectiveness analysis
89. Prevention of vertical transmission of HIV: Analysis of cost effectiveness of options available in South Africa
90. Costeffectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago
91. Mode of delivery and vertical transmission of HIV-1: A review of prospective studies
92. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - A meta-analysis of 15 prospective cohort studies
93. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial
94. The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy
95. Mother-to-child transmission of human immunodeficiency virus in Italy: Temporal trends and determinants of infection
96. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV
97. Ethical issues in perinatal HIV
98. Prevalence of HIV infection in childbearing women in the United States: Surveillance using newborn blood samples
99. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection